A systematic review including 25 studies with a total of 2 853 subjects was abstracted in DARE.
There was no clear benefit for ondansetron compared with metoclopramide or droperidol. The significant heterogeneity found at the 0.1 level (heterogeneity p=0.08) for ondansetron versus metoclopramide was explained by type of surgery and duration of outcome assessment. Outcome type, ondansetron dose level, and the validity criteria did not influence the outcome.
Ondansetron versus metoclopramide (16 RCTs involving 1 981 patients): The pooled RR of post-oprative vomiting using a random-effects model was 0.74 (95% CI: 0.54 to 1.00).